DOCSLIB.ORG

Midwest Healthcare Growth Capital YE 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Midwest Healthcare Growth Capital YE 2014 2014 Year End: Midwest Healthcare Growth Capital Report Amt. Raised Company City Region State Round Description Closed Date (MM) Investors SubSector Source Biotech Device SW/Services Heartland Angels, Gopher https://www.sec.gov/Archives/edgar/dat Angels, Perkins Coie, via the a/1616251/000161625114000001/xslFor Advanced Cooling Therapy Chicago Chicago IL Series A Developer of cooling therapy technologies. 8/14/2014 1.08 TWB Investment Partnership Device mDX01/primary_doc.xml 0.00 1.08 0.00 Bill Gates, Patrick Ryan, David http://www.prnewswire.com/news‐ Deveoper of gene reguluation therapies that Walt, Boon Hwee Koh, Craig releases/aurasense‐therapeutics‐ control the delivery of genetic material into Mundie, Rathmann Family completes‐136‐million‐series‐c‐equity‐ AuraSense Therapeutics Skokie Chicago IL Series C cells. 6/17/2014 13.60 Foundation Biotech investment‐263481661.html 13.60 0.00 0.00 Manufacturer of medicinal drugs. The https://www.sec.gov/Archives/edgar/dat company provides medical products to treat Undisclosed Venture a/1620843/000162084314000002/xslFor Cresco Labs Chicago Chicago IL Angel diseases using marijuana. 10/6/2014 4.00 Investor(s) Biotech mDX01/primary_doc.xml 4.00 0.00 0.00 Develops, manufactures and sells an integrated family of cost‐effective products for http://www.sec.gov/Archives/edgar/data the detection, diagnosis and treatment of Undisclosed Venture /75439/000114420414023078/xslFormD CytoCore Chicago Chicago IL Undisclosed cancer. 4/16/2014 1.53 Investor(s) Device X01/primary_doc.xml 0.00 1.53 0.00 http://www.sec.gov/Archives/edgar/data Developer of a microscopic imaging platform Undisclosed Venture /1528694/000152869414000003/xslFor Diagnostic Photonics Chicago Chicago IL Later for intra‐operative use in clinical settings. 6/12/2014 0.30 Investor(s) Device mDX01/primary_doc.xml 0.00 0.30 0.00 Central Illinois Angels, http://www.sec.gov/Archives/edgar/data Developer of a sensor to monitor the condition Cornerstone Angels, JumpStart /1424668/000142466814000001/xslFor Endotronix Woodridge Chicago IL Later of patients with congestive heart failure. 4/29/2014 1.60 Ventures Device mDX01/primary_doc.xml 0.00 1.60 0.00 https://www.fshealth.com/press/first‐ Provider of online healthcare concierge stop‐health‐receives‐2‐2‐million‐in‐ First Stop Health Chicago Chicago IL Angel service. 3/19/2014 2.20 Undisclosed Angel Investor(s) SW/Services additional‐angel‐financing/ 0.00 0.00 2.20 Provider of a platform for physician‐hospital alignment strategies. The company's DocTime Log platform enables hospitals and health systems to align, creatively design and actively manage the return on investment in physician‐ hospital agreements. It offers automated mobile services for the physicians to log hours https://www.sec.gov/Archives/edgar/dat with a robust tracking to approve time logs a/1595748/000159574814000002/xslFor Ludi Chicago Chicago IL Series A and manage monthly activity. 7/29/2014 1.00 The Martin Companies SW/Services mDX01/primary_doc.xml 0.00 0.00 1.00 Developer of a text mining software for the Undisclosed Angel Investor, Medical Search Technologies Chicago Chicago IL Angel healthcare industry. 4/26/2014 1.20 XLerateHealth SW/Services Pictchbook 0.00 0.00 1.20 http://www.fiercebiotech.com/story/nau Developer of psychiatry and neurology Undisclosed Venture rex‐picks‐25m‐get‐its‐depression‐drugs‐ Naurex Evanston Chicago IL Series B treatment. 5/6/2014 25.00 Investor(s) Biotech through‐phii/2014‐05‐06 25.00 0.00 0.00 Cowen Investments, EcoR1 Capital, Goudy Park Capital, Portola Capital Partners, Sabby Capital, Adams Street Partners, Baxter Ventures, Druid BioVentures, Genesys Capital, H. Lundbeck A/S, Latterell Venture Partners, Northwestern University, https://www.sec.gov/Archives/edgar/dat Developer of psychiatry and neurology PathoCapital, Savitr Capital, a/1467762/000146776214000002/xslFor Naurex Evanston Chicago IL Series C treatment. 12/2/2014 80.00 Takeda Ventures Biotech mDX01/primary_doc.xml 80.00 0.00 0.00 http://www.businesswire.com/news/ho me/20141119005210/en/Novaerus‐ Provider of infection prevention products for Polaris Partners and Fidelity Reaches‐Key‐Milestone‐Funding‐Polaris‐ Novaerus Chicago Chicago IL Growth nursing homes. 11/19/2014 10.00 Biosciences Biotech Partners#.VHy62zHF_Qo 10.00 0.00 0.00 Page 1 of 17 2014 Year End: Midwest Healthcare Growth Capital Report Amt. Raised Company City Region State Round Description Closed Date (MM) Investors SubSector Source Biotech Device SW/Services http://www.purdue.edu/newsroom/relea ses/2014/Q1/ontarget‐laboratories‐ Individual Investor, Pension receives‐15‐million‐to‐develop‐optical‐ OnTarget Laboratories Northbrook Chicago IL Corporate Developer of optical imaging technologies. 3/11/2014 15.00 Fund of the Christian Church Device imaging‐technology‐for‐cancer.html 0.00 15.00 0.00 http://bluesky.chicagotribune.com/origin als/chi‐opternative‐online‐eye‐exam‐ Opternative Chicago Chicago IL Seed Provider of online eye‐examination services. 2/25/2014 1.00 Tribeca Venture Partners SW/Services bsi,0,0.story 0.00 0.00 1.00 LionBird and undisclosed Angel http://www.physiq.com/news‐events/pr‐ PhysIQ Naperville Chicago IL Series A Developer of personalized predictive analytics. 7/24/2014 4.60 investors SW/Services introducing‐physiq‐072414/ 0.00 0.00 4.60 Developer of imaging devices for diagnosing cancer. The company's s products include https://www.sec.gov/Archives/edgar/dat nanoarrays that take images of molecular ARCH Venture Partners, a/1598556/000159855614000001/xslFor PixelEXX Systems Chicago Chicago IL Later signals associated with cellular activity. 1/29/2014 0.65 BioGenerator, Prolog Ventures SW/Services mDX01/primary_doc.xml 0.00 0.00 0.65 Provider of supply‐chain and purchasing‐ http://southernalpha.com/procured‐ Procured Chicago Chicago IL A optimization software for hospitals. 3/5/2014 4.00 FCA Venture Partners SW/Services health‐raises‐4‐0m‐series‐fca/ 0.00 0.00 4.00 Developer of software products to automate healthcare data collection and analytics. The company's software services streamline the reporting process and automate the https://www.sec.gov/Archives/edgar/dat identification of root causes behind usage a/1508806/000150880614000007/xslFor SA Ignite Chicago Chicago IL Series B problems. 7/15/2014 5.37 Undisclosed SW/Services mDX01/primary_doc.xml 0.00 0.00 5.37 http://mobihealthnews.com/32819/swip Undisclosed Venture esense‐raises‐1‐7m‐for‐connected‐hand‐ SwipeSense Evanston Chicago IL Series A2 Provider of a portable hand hygiene device. 5/5/2014 1.75 Investor(s) Device hygiene‐dispensers‐in‐hospitals/ 0.00 1.75 0.00 Heritage Group, Foundation Medical Partners, GE Ventures, Provider of clinical integration and data and North Bridge Growth http://valencehealth.com/news/valence‐ Valence Health Chicago Chicago IL Series B management software. 11/19/2014 15.00 Equity SW/Services health‐secures‐additional‐growth‐capital 0.00 0.00 15.00 http://www.sec.gov/Archives/edgar/data Developer of a drug on molecular defects in Illinois Ventures, Level 5 /1572746/000157274614000001/xslFor Vanquish Oncology Champaign Champaign IL Series A specific cancer cells. 4/10/2014 4.39 Partners, University of Illinois Biotech mDX01/primary_doc.xml 4.39 0.00 0.00 https://www.sec.gov/Archives/edgar/dat Developer of regenerative medical products a/1579613/000157961314000003/xslFor Regenerative Medical Solutions Chicago Chicago IL Early Stage VC for diabetes treatment. 11/7/2014 0.38 Undisclosed Biotech mDX01/primary_doc.xml 0.38 0.00 0.00 Developer of Altum, a minimally invasive cure http://www.sec.gov/Archives/edgar/data for lumbar spinal stenosis that maintains the Undisclosed Venture /1508803/000150880314000003/xslFor Innovative Surgical Designs Bloomington Bloomington IN Early natural dynamics of the spine. 6/30/2014 0.25 Investor(s) Device mDX01/primary_doc.xml 0.00 0.25 0.00 Developer of non‐resorbable films which separate adjacent organs from adhering to Sintact Medical Systems Bloomington Bloomington IN Seed each other after surgery. 8/26/2014 0.03 Health Wildcatters Device PitchBook 0.00 0.30 0.00 Provider of quantitative bioanalytical support http://www.sec.gov/Archives/edgar/data for pre‐clinical and Phase I through Phase III /1595728/000117885814000001/xslFor AIT Bioscience Indianapolis Indianapolis IN Early clinical trials. 1/7/2014 1.00 HALO SW/Services mDX01/primary_doc.xml 0.00 0.00 1.00 Developer of a patented algae cultivation technology and efficient production process for high volume production of nutraceutical Indiana Seed Fund II, Angel https://www.insideindianabusiness.com/ Algaeon Indianapolis Indianapolis IN Early and animal / fish feed products. 5/13/2014 2.75 investors Biotech newsitem.asp?ID=65097 2.75 0.00 0.00 Page 2 of 17 2014 Year End: Midwest Healthcare Growth Capital Report Amt. Raised Company City Region State Round Description Closed Date (MM) Investors SubSector Source Biotech Device SW/Services Developer of a patented algae cultivation technology and efficient production process https://www.sec.gov/Archives/edgar/dat for high volume production of nutraceutical Undisclosed Venture a/1560376/000156037614000001/xslFor Algaeon Indianapolis Indianapolis IN Early and animal / fish feed products. 9/16/2014 0.05 Investor(s) Biotech mDX01/primary_doc.xml 0.05 0.00 0.00 http://www.sec.gov/Archives/edgar/data Developer of case/tray systems for orthopedic /1599940/000159994014000001/xslFor Arcamed Indianapolis Indianapolis IN Growth and surgical industries. 2/12/2014 0.50 Heron Capital Device mDX01/primary_doc.xml 0.00 0.50 0.00 http://www.sec.gov/Archives/edgar/data Provider of custom design and manufacturing /1525032/000152503214000002/xslFor Biologics Modular Brownsburg Indianapolis IN Growth facilities for laboratories based on needs. 3/13/2014 0.03 Angel Investors Biotech mDX01/primary_doc.xml 0.03 0.00 0.00 Developer of orphan drugs for mitochondrial http://www.sec.gov/Archives/edgar/data diseases using a proprietary protein Undisclosed Venture /1603367/000160336714000003/xslFor Chondrial Therapeutics Indianapolis Indianapolis IN Early replacement platform.
Load more

Recommended publications
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • Investor Book (PDF)
    INVESTOR BOOK EDITION OCTOBER 2016 Table of Contents Program 3 Venture Capital 10 Growth 94 Buyout 116 Debt 119 10 -11 November 2016 Old Billingsgate PROGRAM Strategic Partners Premium Partners MAIN STAGE - Day 1 10 November 2016 SESSION TITLE COMPANY TIME SPEAKER POSITION COMPANY Breakfast 08:00 - 10:00 CP 9:00 - 9:15 Dr. Klaus Hommels Founder & CEO Lakestar CP 9:15 - 9:30 Fabrice Grinda Co-Founder FJ Labs 9:35 - 9:50 Dr. Klaus Hommels Founder & CEO Lakestar Fabrice Grinda Co-Founder FJ Labs Panel Marco Rodzynek Founder & CEO NOAH Advisors 9:50 - 10:00 Chris Öhlund Group CEO Verivox 10:00 - 10:10 Hervé Hatt CEO Meilleurtaux CP Lead 10:10 - 10:20 Martin Coriat CEO Confused.com Generation 10:20 - 10:30 Andy Hancock Managing Director MoneySavingExpert K 10:30 - 10:45 Carsten Kengeter CEO Deutsche Börse Group 10:45 - 10:55 Carsten Kengeter CEO Deutsche Börse Group FC Marco Rodzynek Founder & CEO NOAH Advisors CP 10:55 - 11:10 Nick Williams Head of EMEA Global Market Solutions Credit Suisse 11:10 - 11:20 Talent 3.0: Science meets Arts CP Karim Jalbout Head of the European Digital Practice Egon Zehnder K 11:20 - 11:50 Surprise Guest of Honour 11:50 - 12:10 Yaron Valler General Partner Target Global Mike Lobanov General Partner Target Global Alexander Frolov General Partner Target Global Panel Shmuel Chafets General Partner Target Global Marco Rodzynek Founder & CEO NOAH Advisors 12:10 - 12:20 Mirko Caspar Managing Director Mister Spex 12:20 - 12:30 Philip Rooke CEO Spreadshirt CP 12:30 - 12:40 Dr.
    [Show full text]
  • A Framework for a Public-Private Partnership to Increase The
    A national laboratory of the U.S. Department of Energy Office of Energy Efficiency & Renewable Energy National Renewable Energy Laboratory Innovation for Our Energy Future Enhancing Commercial Technical Report NREL/TP-110-40463 Outcomes from R&D May 2007 A Framework for a Public–Private Partnership to Increase the Yield of Federally Funded R&D Investments and Promote Economic Development L.M. Murphy Manager, Enterprise Development Programs National Renewable Energy Laboratory P. Jerde Executive Director Robert H. and Beverly A. Deming Center for Entrepreneurship, Leeds School of Business University of Colorado, Boulder L. Rutherford Venture Partner Vista Ventures R. Barone 2008 MS/MBA Candidate Department of Environmental Studies and Leeds School of Business University of Colorado, Boulder NREL is operated by Midwest Research Institute ● Battelle Contract No. DE-AC36-99-GO10337 Enhancing Commercial Technical Report NREL/TP-110-40463 Outcomes from R&D May 2007 A Framework for a Public–Private Partnership to Increase the Yield of Federally Funded R&D Investments and Promote Economic Development L.M. Murphy Manager, Enterprise Development Programs National Renewable Energy Laboratory P. Jerde Executive Director Robert H. and Beverly A. Deming Center for Entrepreneurship, Leeds School of Business University of Colorado, Boulder L. Rutherford Venture Partner Vista Ventures R. Barone 2008 MS/MBA Candidate Department of Environmental Studies and Leeds School of Business University of Colorado, Boulder Prepared under Task No. 1100.1000 National Renewable Energy Laboratory 1617 Cole Boulevard, Golden, Colorado 80401-3393 303-275-3000 • www.nrel.gov Operated for the U.S. Department of Energy Office of Energy Efficiency and Renewable Energy by Midwest Research Institute • Battelle Contract No.
    [Show full text]
  • Overview of Cleveland's Health Care Industry and Bioenterprise Initiative
    Overview of Cleveland’s Health Care Industry and BioEnterprise Initiative November 14, 2007 1 Overview • Regional Health Care Base: 2002 • Transformation: Role of State • BioEnterprise and Entrepreneurship • Lessons Learned 2 Cleveland Health Care Base Nationally-recognized leaders in clinical care and research … • > $450 Million in annual research • Numerous nationally-distinctive programs including: • Cardiovascular • Cancer • Neurology • Orthopedics • Surgery • Pediatrics • Medical imaging • Biomedical engineering • Stem cells & tissue engineering • Advanced materials • Molecular diagnostics • Anti-infectives • Prions • Destination for innovation and care 3 Cleveland Health Care Base … a broad industry base… • ~500 health care Biopharma- companies in region ceutical 16% • Five >$1 billion companies Device/ or divisions Equipment Other 68% • Over 20,000 employees 6% Health Care Services/IT 10% 4 Weak Commercialization …However, few companies were attracting growth equity CLEVELAND AREA CLEVELAND AREA HEALTH CARE VENTURE INVESTMENT HEALTH CARE VENTURE INVESTMENT $ Millions Companies Financed 6 33 5 8 2 01 02 0 0 0 001 2 2 2 20 5 Source: Dow Jones Venture Wire; Venture Source; BioEnterprise Broad Effort Required • Community- People wide effort Pipeline • Collaboration Growth Clinical • Connectedness … regionally Capital and nationally 6 2002: Commitment to Growth • Private • Renewed focus on entrepreneurs and innovation • Technology transfer culture capabilities significantly enhanced • Investment firms and professional services • Public
    [Show full text]
  • Role of Angel Investors in Capital Formation Who Are Angel Investors?
    Role of Angel Investors in Capital Formation Who are Angel Investors? • Often successful entrepreneurs or retired business persons – Active investors providing money, expertise, and their network – Contribute to their local ecosystem (mentoring, judging, educating) • Accredited investors – SEC definition • Invest their own money (not money managers) • Generally invest in local companies • Invest in businesses not run by family Financing Life Cycle Proof-of Product Product Manufacturing/ Discovery Concept Design Development Delivery Idea Pre-seed Seed Start-up Expansion/Mezzanine Funding Funding Funding Operating Cap. Founder Venture Funds Friends and Family Angels Institutional Equity Angel Groups Loans / Bonds Seed Funds Investment Landscape— Company Valuation Company Continue, Prep Technology Proof-of Go To - Product Build and Scale IPO or Discovery Concept Market Stage Deliver M&A Investment $100K $500K $1.5M $2-5M $15M $50M Needed Funding Pre-seed Seed Start-up Expansion Operating & Stage Funding Funding Funding Funding Growth Founder Individual Angels Seed Funds Source SBIR Phase 1 & 2 Venture Funds of Funding Friends & Family Angel Groups Institutional Equity Business Gov. Economic Dev. Loans / Bonds Incubators Company $100K $1.5M $4M $10M $75M $250M Valuation Angel Investors • TYPES - all shapes and sizes! – Friends and Family – Unsophisticated or Sophisticated – Guardian Angels > active advisors/mentors – Passive – Super Angels – Angel Networks /Funds – Single Family Offices Growth in Number of American Angel Groups 400 350 300
    [Show full text]
  • FT PARTNERS RESEARCH 2 Fintech Meets Alternative Investments
    FT PARTNERS FINTECH INDUSTRY RESEARCH Alternative Investments FinTech Meets Alternative Investments Innovation in a Burgeoning Asset Class March 2020 DRAFT ©2020 FinTech Meets Alternative Investments Alternative Investments FT Partners | Focused Exclusively on FinTech FT Partners’ Advisory Capabilities FT Partners’ FinTech Industry Research Private Capital Debt & Raising Equity Sell-Side / In-Depth Industry Capital Buy-Side Markets M&A Research Reports Advisory Capital Strategic Structuring / Consortium Efficiency Proprietary FinTech Building Advisory FT Services FINTECH Infographics Partners RESEARCH & Board of INSIGHTS Anti-Raid Advisory Directors / Advisory / Monthly FinTech Special Shareholder Committee Rights Plans Market Analysis Advisory Sell-Side Valuations / LBO Fairness FinTech M&A / Financing Advisory Opinion for M&A Restructuring Transaction Profiles and Divestitures Named Silicon Valley’s #1 FinTech Banker Ranked #1 Most Influential Person in all of Numerous Awards for Transaction (2016) and ranked #2 Overall by The FinTech in Institutional Investors “FinTech Excellence including Information Finance 40” “Deal of the Decade” • Financial Technology Partners ("FT Partners") was founded in 2001 and is the only investment banking firm focused exclusively on FinTech • FT Partners regularly publishes research highlighting the most important transactions, trends and insights impacting the global Financial Technology landscape. Our unique insight into FinTech is a direct result of executing hundreds of transactions in the sector combined with over 18 years of exclusive focus on Financial Technology FT PARTNERS RESEARCH 2 FinTech Meets Alternative Investments I. Executive Summary 5 II. Industry Overview and The Rise of Alternative Investments 8 i. An Introduction to Alternative Investments 9 ii. Trends Within the Alternative Investment Industry 23 III. Executive Interviews 53 IV.
    [Show full text]
  • Dr Sam Goodman [email protected]/650-364-1151) Senior Adjunct Professor, Department of Finance & Economics Edward S
    Dr Sam Goodman [email protected]/650-364-1151) Senior Adjunct Professor, Department of Finance & Economics Edward S. Ageno School of Business GOLDEN GATE UNIVERSITY Summer Term, 2009 San Jose Campus Mon 6-8:40pm FI 318 – VENTURE CAPITAL & START-UP FINANCING Course Outline Course Description: This course examines the strategic and financial issues facing high-growth start-ups. Students develop a sophisticated understanding of the tools and techniques employed by successful entrepreneurs in raising start-up, growth, and acquisition capital for their ventures. Students also will explore alternative financing sources, notably venture capital and angel investors. In addition, students will review the exit strategies available to companies, including IPOs and mergers. Topics discussed include: the history and current direction of the venture capital industry, valuation techniques for new ventures and established private firms, raising venture capital and alternative financing, entrepreneurial management issues in capital raising, maintaining control and direction, and harvesting the venture via IPO or merger. Through two short case studies and an individual project, each student will have an opportunity to personalize the learning process by applying the analytical tools of entrepreneurial finance to real cases and by selecting and studying a highly entrepreneurial industry of personal interest. Finally, all of the course material is based on the key underlying premise that it’s important for each student to understand the perspective of both
    [Show full text]
  • Clarity on Mergers and Acquisitions
    Clarity on Mergers & Acquisitions Swiss deal flows hit record high January 2019 16 2018 activity and 2019 outlook An industry-by-industry look at last year’s deals and what you might expect over the next 12 months. 22 Private Equity and the Swiss economy SECA’s General Secretary shares his insights into how Private Equity makes the Swiss economy stronger. 76 Detailed 2018 transaction list View the M&A deals that involved a Swiss buyer, seller or target. 28 4 12 6 18 10 Clarity on Mergers & Acquisitions CONTENT Clarity on Mergers & Acquisitions EDITORIAL CHAPTER II 3 Switzerland’s M&A activity 34 Industry Sector Pages sets a new record 36 Chemicals 40 Commodities CHAPTER I 44 Consumer Markets Overview 48 Financial Services 52 Industrial Markets 12 Media headlines 56 Pharmaceuticals & Life Sciences 60 Power & Utilities 14 Summary 64 Private Equity 68 Real Estate 72 Technology, Media & Telecommunications Focus Topic: Private Equity CHAPTER III 22 What is it and how does it work? 76 List of Swiss M&A 26 The changing legal and regulatory framework for Private Equity in Switzerland transactions in 2018 30 Interview with Maurice Pedergnana, SECA: CHAPTER IV The national economy is healthier thanks to private equity 110 Tombstones 116 PINBOARD 117 CONTACT & IMPRINT 1 2 Clarity on Mergers & Acquisitions EDITORIAL Switzerland’s M&A activity sets a new record activity. In fact, acquisitions by Private Equity houses once more exceeded exits, in a further sign of the growing importance of this community on the M&A landscape. A considerable amount of the M&A activity observed last year is due to changing consumer behaviors and rapid advances in technology – not least i4.0, the ’fourth industrial revolution’ that is upon us thanks to developments in artificial intelligence.
    [Show full text]
  • HEALTHCARE INDUSTRY ASSOCIATION (HCIA) RESUME BOOK Columbia Healthcare and Pharmaceutical Management Program
    HEALTHCARE INDUSTRY ASSOCIATION (HCIA) RESUME BOOK Columbia Healthcare and Pharmaceutical Management Program CLASS OF 2017 CLASS OF 2018 CONTENTS 2017 RESUMES 11 ROBERT MORIN 20 SONYA NANDA JT MUNCH JAY NICHOLAS 3 LISA AULT RICHARD MURPHEY LIZ NYLUND JULIE BAILEY BORMAN ELISA 12 SAM NELSON 21 PATIENCE OLANITORI ADAM NORRIS MILICA PAVLOVIC 4 WILLIAM CAMPBELL COURTNEY PITTENGER ALLISON PERRIN GUIDO CASTAGNOLA CECE CHEN 13 VARNA RAMAN 22 PRAMOD PRASAD MORGAN SHATTUCK DARPITA PUROHIT 5 JAMES CHEUNG STEPH SHAW FENG QIAN BIRCE CIRAVOGLU EVAN COHEN 14 XIN (TONY) SHU 23 DIVYA RAJ ALEXANDER APARNA RAMAKRISHNAN 6 ELIZABETH COLONNA VON FALENHAUSEN ISOBEL ROSENTHAL CHRISTIAN DUNNE PHILONG DUONG 24 MEREDITH SHIELDS 2018 RESUMES JASON ZE SU 7 LEV ELDEMIR KEITH TABIN PAWEL FEDEJKO 14 YAPRAK BARAN 25 JEFFERSON TAYLOR EMILY GARVIN 15 JAMES BEALL ANGELA WANG DIANA BERKOVITS 8 RACHEL HAN MALLORY WEST CAROLYN HEISLER TRAVIS BOWDEN 26 ELLEN YANG QIAN HU 16 JESSICA CHO THORSON ZACH 9 SCOTT JOHNSON JOSEPH COSENTINO HILLARY KAPLAN KATIE DEAN VICTORIA LAI 17 ADAM ESCALANTE 10 SHREYAS LAKSHMINARAYAN MATTHEW FOXMAN JOSEPHINE LINTHORST ANDREW GOTTESDIENER JAMIE MEYERSON 18 STEPHANIE HU NAMWON JUNG JESSICA KIM 19 CHASE KNIGHT MOLLY MAGNUSON ALEX MARGOLIS HCIA AT COLUMBIA BUSINESS SCHOOL The Healthcare Industry Association (HCIA) is committed to expanding opportunities outside of the classroom for Columbia Business School students to learn about the many segments of the healthcare industry. Working in close collaboration with the Healthcare and Pharmaceutical Management Program, HCIA organizes a variety of activities throughout the year. It offers members the opportunity to increase their knowledge of the healthcare industry, expand their professional networks, learn about diverse career paths, and secure internships, full-time opportunities, and in-semester projects.
    [Show full text]
  • WBAF ACADEMY - Workshops 2019
    WBAF ACADEMY - Workshops 2019 World Congress of Angel Investors 2019 Unlocking the Potential for Innovation as Developing Global Partnerships for Economic Development 19 February 2019, Tuesday Swissotel The Bosphorus Istanbul Zurich Hall 09:00 Workshop 1 : Making big returns investing in small businesses: An entrepreneurial approach to investing Investors complain there are not enough good deals. Entrepreneurs complain that there is not enough money. The current investment structures are keeping the two parties apart. 50% of the Worlds GDP comes from small to medium enterprises, yet most of it is off limits to sophisticated investors. Learn how adopting an entrepreneurial approach with a fixation on liquidity can allow all investors to make big returns investing in small business. WBAF Faculty Member to lead the session Callum Laing, Partner in Unity Group Private Equity Callum Laing is an entrepreneur and investor. He is partner in Unity Group Private Equity, Co-Founder and Chairman of MBH Corporation PLC, and is the originator of ‘Accelerated Venture Capital’ (AVC). Author of two best-selling business books, publisher of more than 700 interviews with entrepreneurs and investors, he is also the WBAF High Commissioner for Singapore. 10:00 Workshop 2 : Combining the best of angel investing and venture capital According to the latest EBAN figures, the average investment for an angel investor in a sin- gle business in 2017 was EUR 25,000, and EUR 182,000 for an angel network. At the same time, venture capital investment starts with significantly larger numbers. Businesses looking to raise $500K to $2M often struggle. It’s the valley of death.
    [Show full text]
  • A Randomized Field Experiment on Early Stage Investments
    Is it Just the Idea that Matters? A Randomized Field Experiment on Early Stage Investments Shai Bernstein, Arthur Korteweg, and Kevin Laws* Abstract Which start-up characteristics are most important to investors in early-stage firms? This paper uses a randomized field experiment involving 4,500 active, high profile, early stage investors, implemented through AngelList, an online platform that matches investors with start-ups that are seeking capital. The experiment randomizes investors’ information sets on “featured” start-ups through the use of nearly 17,000 emails. Investors respond strongly to information about the founding team, whereas they do not respond to information about either firm traction or existing lead investors. This result is driven by the most experienced and successful investors. The least experienced investors respond to all categories of information. We present evidence that the information materially impacts investment rates in start-up companies. The results suggest that, conditional on the quality of the idea, information about human assets is highly important for the success of early stage firms. JEL classification: G32, L26, D23 Keywords: Angels, Early stage firms, Entrepreneurship, Crowdfunding, Theory of the firm Current Draft: March, 2014 * Shai Bernstein ([email protected]) and Arthur Korteweg ([email protected]) are from Stanford Graduate School of Business, and Kevin Laws is from AngelList, LLC. We thank Wayne Ferson, Steve Kaplan, seminar participants at Harvard Business School, UCLA, University of Illinois at Urbana-Champaign, University of Maryland, University of Southern California, University of Texas at Austin, and brown bag participants at the UC Berkeley Fung Institute and Stanford for helpful comments.
    [Show full text]
  • The Impact of Angel Investors on Founders of New Ventures in the Medical Technology Industry
    The Impact of Angel Investors on Founders of New Ventures in the Medical Technology Industry By Alan R. Braly BS, Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218 MBA, Harvard Business School, Harvard University, Boston, MA 02163 SUBMITTED TO THE HARVARD - MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN HEALTH SCIENCES AND TECHNOLOGY ARCHIVES AT THE MASSAH TUTE MASSACHUSETTS INSTITUTE OF TECHNOLOGY SEP 2) 2J September 2011 1 @2011 Alan R. Braly. All rights reserved. The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium no known or hereafter created. Signature of Author: Harvard MI Division of Health Sciences and Technology September 1, 2011 Certified by: Carl M. Berke, PhD Partner, Partners Innovation Fund, Partners Healthcare Lecturer, Harvard-MIT Division of Health Sciences and Technology I \P Thesis Supervisor Certified Jonathan J.Fleming, MPA Managing General Partner, Oxford Bioscience Partners Director, Leerink Swann LLC Senior Lecturer, MIT Sloan School of Management Thesis Supervisor Accepted by: Ram Sasisekharan, PhD Director, Harvard-MIT Division of Health Sciences and Technology Edward Hood Taplin Professor of Health Sciences & Technology and Biological Engineering This page intentionally left blank. Dedications To my family, unyielding in their support of my extensive (and long-running) graduate educational endeavors... and equally unyielding in their quickness to knock me down a notch if the MIT-Harvard dual- degree nerd in me threatened to escape.
    [Show full text]